Jun 2026 (Q2 FY26) — Aug 5, 2026
Delek Logistics Partners Q2 FY26 — Record Crude Volumes and Reaffirmed EBITDA Guidance
Read the full callDelek Logistics Partners (DKL) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Delek Logistics Partners earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 385 | +56.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 16.1 | −5.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. |
Price
$55.94 −0.83% · −$0.47
Performance +26.3% 1Y
1Y: $44.29 on 14 Oct 2025 → $55.94. High $60.31 (31 Jul 2026), low $43.3 (16 Oct 2025).
- Previous close
- $56.41
- 52-week range
- $43.3 – $60.31
- One year
- +28.36%
Overview
- Symbol
- DKL
- Sector
- Energy
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Delek Logistics Partners earnings calls (DKL)
Financials
What the filings say
Net profit, year on year: −17% (quarter to mar 2026 against mar 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 214 | 210 | 250 | 246 | 261 | 256 | 297 | 385 |
| Expenses | 182 | 172 | 202 | 194 | 216 | 219 | 257 | 323 |
| Operating profit | 32 | 38 | 48 | 52 | 45 | 36 | 40 | 62 |
| Operating margin | 14.9% | 18.1% | 19.0% | 21.3% | 17.4% | 14.3% | 13.4% | 16.1% |
| Interest | 37 | 38 | 41 | 42 | 48 | 48 | 52 | 70 |
| Profit before tax | 34 | 35 | 39 | 45 | 46 | 47 | 32 | 29 |
| Tax rate | 0.4% | −0.1% | 0.5% | 0.6% | 0.8% | −0.7% | 0.0% | 0.0% |
| Net profit | — | 35 | 39 | — | — | 47 | 32 | — |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Fixed assets | 313 | 295 | 465 | 449 | 924 | 936 | 1,064 | 1,424 |
| Total assets | 625 | 744 | 956 | 935 | 1,679 | 1,642 | 2,042 | 2,779 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 153 | 130 | 193 | 275 | 192 | 225 | 206 | 237 |
| Cash from investing | -228 | -147 | -123 | -16 | -770 | -90 | -385 | -444 |
| Cash from financing | 75 | 18 | -71 | -259 | 582 | -140 | 180 | 213 |
| Net cash flow | -0 | 1 | -1 | 0 | 4 | -4 | 2 | 6 |
| Capital expenditure | -13 | -9 | -13 | -23 | -141 | -96 | -129 | -268 |
| Free cash flow | 140 | 121 | 180 | 252 | 51 | 129 | 77 | -31 |
Insider filings
46 filings between Nov 5, 2025 and Sep 10, 2026.
Open market
decisions to buy or sellPurchases
$750.0K
5 purchases by 5 insiders
Sales
$60.9K
5 sales by 1 insider
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 13
- Award — granted as compensation
- 22
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 disposition to issuer.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Yemin Ezra Uzi | $300.0K | — | Aug 13, 2026 |
| Hobbs Mark Wayne | $200.0K | — | Aug 13, 2026 |
| Soreq Avigal | $125.0K | — | Aug 13, 2026 |
| Spiegel Reuven | $50.0K | $60.9K | Aug 13, 2026 |
| Wright Robert G. | $75.0K | — | Aug 13, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2026 | Spiegel Reuven EVP, Delek Logistics | Tax withheld | 743 | $42.4K |
| Sep 10, 2026 | Soreq Avigal President | Tax withheld | 3,038 | $173.2K |
| Sep 10, 2026 | Hobbs Mark Wayne EVP | Tax withheld | 659 | $37.6K |
| Sep 10, 2026 | Wright Robert G. EVP, Chief Financial Officer | Tax withheld | 229 | $13.1K |
| Aug 13, 2026 | Wright Robert G. EVP, Chief Financial Officer | Purchase | 1,500 | $75.0K |
| Aug 13, 2026 | Soreq Avigal President | Purchase | 2,500 | $125.0K |
| Aug 13, 2026 | Yemin Ezra Uzi Chairman | Purchase | 6,000 | $300.0K |
| Aug 13, 2026 | Hobbs Mark Wayne EVP | Purchase | 4,000 | $200.0K |
| Aug 13, 2026 | Spiegel Reuven Executive Vice President, DKL | Purchase | 1,000 | $50.0K |
| Jun 10, 2026 | Green Frederec Director | Award | 2,476 | $130.0K |
| Jun 10, 2026 | Hobbs Mark Wayne EVP | Tax withheld | 350 | $18.4K |
| Jun 10, 2026 | Wright Robert G. EVP, Chief Financial Officer | Tax withheld | 74 | $3.9K |
| Jun 10, 2026 | Kelly Gennifer F. Director | Award | 2,476 | $130.0K |
| Jun 10, 2026 | Brillon Sherri Anne Director | Award | 2,476 | $130.0K |
| Jun 10, 2026 | Soreq Avigal President | Tax withheld | 1,646 | $86.4K |
| Jun 10, 2026 | Yemin Ezra Uzi Chairman | Award | 2,476 | $130.0K |
| Jun 10, 2026 | Spiegel Reuven Executive Vice President, DKL | Tax withheld | 1,485 | $77.9K |
| Jun 10, 2026 | Brown Charles J III Director | Award | 2,476 | $130.0K |
| Jun 10, 2026 | GADD ERIC D Director | Award | 2,476 | $130.0K |
| Jun 10, 2026 | HADDOCK RON W Director | Award | 2,476 | $130.0K |
| Jun 10, 2026 | McWatters Denise Clark EVP, Gen Counsel & Corp Sec | Tax withheld | 1,277 | $67.0K |
| Apr 1, 2026 | Delek US Holdings, Inc. Director | Disposition to issuer | 359,372 | — |
| Mar 10, 2026 | Wright Robert G. EVP, Chief Financial Officer | Award | 2,357 | $0 |
| Mar 10, 2026 | Hobbs Mark Wayne EVP | Tax withheld | 461 | $24.4K |
| Mar 10, 2026 | Hobbs Mark Wayne EVP | Award | 4,715 | $0 |
| Mar 10, 2026 | Wright Robert G. EVP, Chief Financial Officer | Tax withheld | 831 | $44.1K |
| Mar 10, 2026 | Wright Robert G. EVP, Chief Financial Officer | Award | 1,922 | $0 |
| Mar 10, 2026 | Soreq Avigal President | Tax withheld | 2,201 | $116.7K |
| Mar 10, 2026 | Soreq Avigal President | Award | 21,218 | $0 |
| Mar 10, 2026 | Spiegel Reuven Executive Vice President, DKL | Award | 7,544 | $0 |
| Mar 10, 2026 | McWatters Denise Clark EVP, Gen Counsel & Corp Sec | Tax withheld | 1,439 | $76.3K |
| Mar 10, 2026 | Israel Joseph EVP | Tax withheld | 575 | $30.5K |
| Mar 10, 2026 | Israel Joseph EVP | Award | 5,658 | $0 |
| Mar 9, 2026 | Israel Joseph EVP | Tax withheld | 168 | $8.7K |
| Mar 4, 2026 | Spiegel Reuven Executive Vice President, DKL | Sale 10b5-1 plan | 250 | $13.3K |
| Feb 4, 2026 | Spiegel Reuven Executive Vice President, DKL | Sale 10b5-1 plan | 250 | $13.1K |
| Jan 5, 2026 | Spiegel Reuven Executive Vice President, DKL | Sale 10b5-1 plan | 250 | $11.7K |
| Dec 10, 2025 | Hobbs Mark Wayne EVP | Tax withheld | 461 | $20.8K |
| Dec 10, 2025 | Israel Joseph EVP | Tax withheld | 575 | $25.9K |
| Dec 10, 2025 | Wright Robert G. EVP, Chief Financial Officer | Tax withheld | 499 | $22.5K |
| Dec 10, 2025 | Soreq Avigal President | Tax withheld | 2,201 | $99.1K |
| Dec 10, 2025 | Spiegel Reuven Executive Vice President, DKL | Tax withheld | 972 | $43.8K |
| Dec 10, 2025 | McWatters Denise Clark EVP, Gen Counsel & Corp Sec | Tax withheld | 987 | $44.4K |
| Dec 9, 2025 | Israel Joseph EVP | Tax withheld | 168 | $7.6K |
| Dec 4, 2025 | Spiegel Reuven Executive Vice President, DKL | Sale 10b5-1 plan | 250 | $11.5K |
| Nov 5, 2025 | Spiegel Reuven Executive Vice President, DKL | Sale 10b5-1 plan | 250 | $11.3K |
| Oct 6, 2025 | Spiegel Reuven Executive Vice President, DKL | Sale 10b5-1 plan | 250 | $11.3K |
| Sep 12, 2025 | Spiegel Reuven Executive Vice President, DKL | Sale 10b5-1 plan | 250 | $11.3K |
| Sep 10, 2025 | Spiegel Reuven Executive Vice President, DKL | Tax withheld | 972 | $42.8K |
| Sep 10, 2025 | Israel Joseph EVP, Operations | Tax withheld | 939 | $41.3K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Delek Logistics Partners, LP
Free account. Everything above stays public.
Write why you follow Delek Logistics Partners, LP and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading